Endovastec(SH:688016) Sou Hu Cai Jing·2025-11-05 17:42Summary of Key Points Core Viewpoint - The company, Xinmai Medical, is undergoing significant governance changes, including the cancellation of its supervisory board and the introduction of new management policies, which may impact its operational structure and risk management strategies [1][3]. Trading Information - On November 5, 2025, Xinmai Medical's stock closed at 98.15 yuan, down 1.2%, with a turnover rate of 1.3% and a trading volume of 16,000 hands, resulting in a transaction value of 1.58 billion yuan [1]. - The net outflow of main funds on the same day was 11.473 million yuan, accounting for 7.27% of the total transaction value [1][3]. - Retail investors showed a net inflow of 18.9695 million yuan, representing 12.03% of the total transaction value [1]. Company Announcements - Xinmai Medical will hold its first extraordinary general meeting of shareholders on November 14, 2025, to discuss three key proposals: 1. The cancellation of the supervisory board, with its functions transferred to the audit committee of the board of directors, along with amendments to the company's articles of association and necessary business registration changes. 2. Amendments to eight management regulations, including the rules for shareholder meetings and board meetings, in accordance with the new Company Law and relevant regulatory requirements. 3. The proposal to purchase liability insurance for directors and senior management with an annual coverage of 50 million yuan and a premium not exceeding 300,000 yuan, with a 12-month insurance period [1].